Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome

JACC: Cardiovascular Interventions

Volumn 8, Issue 1, 2015, Pages 201-213

  Navarese, Eliano Pio ^a,b,c,d   Schulze, Volker ^b,c,d   Andreotti, Felicita ^c,d,e   Kowalewski, Mariusz ^c,d,f   Kołodziejczak, Michalina ^c,d,g   Kandzari, David E ^h   Rassaf, Tienush ^b,c,d   Gorny, Bartosz ^c,d,e   Brockmeyer, Maximilian ^b,c,d   Meyer, Christian ^b,c,d   Berti, Sergio ^a,i   Kubica, Jacek ^c,d,g   Kelm, Malte ^b,c,d   Valgimigli, Marco ^j  

^a CNR   (Italy)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c Syst Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE Research Network   (Poland)

^d Syst Investigation and Research on Interventions and Outcomes   (Germany)

^e CATHOLIC UNIVERSITY   (Italy)

^f IPHC in Bydgoszcz   (Poland)

^g NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^h PIEDMONT HEART INSTITUTE   (United States)

ⁱ Heart Hospital   (Italy)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Acute coronary syndrome; Bivalirudin; GP IIb IIIa inhibitor; Heparin; Meta analysis

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PRASUGREL; TICAGRELOR; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIA DRIVEN REVASCULARIZATION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CORONARY THROMBOSIS; DRUG EFFECTS; METABOLISM; MORTALITY; MYOCARDIAL INFARCTION; RISK; RISK FACTOR; THROMBOCYTE; TIME; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; BLOOD PLATELETS; CHI-SQUARE DISTRIBUTION; CORONARY THROMBOSIS; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84921340851     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.10.003     Document Type: Article

References (31)

1. American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O' Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61:e78-140.
2. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999-3054.
3. Steinberg DH, Shah P, Kinnaird T, et al. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris. Am J Cardiol 2008;102:160-4.
4. Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 2011;9:1902-15.
5. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Lancet 2014;384:1849-58.
6. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339:b2700.
7. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Available at: www.cochrane.org/resources/handbook. Accessed May 1, 2014.
8. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344-51.
9. Higgins JP, Thompson SG, Deeks JJ, Altman D. Measuring inconsistency in meta-analyses. BMJ 2003 Sept 6;327:557-60.
10. Fleiss J. Analysis of data from multiclinic trials. Control Clin Trials 1986;7:267-75.
11. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203-16.
12. Aoki J, Lansky AJ, Mehran R, et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2009;119:687-98.
13. Aoki J, Stone GW, Mehran R, et al. Subacute Stent Thrombosis in Patients with Acute Coronary Syndromes Treated with Bare Metal and Drug-Eluting Stents: the ACUITY Trial. Columbia University Medical Center, Cardiovascular Research Foundation, New York City. Available at: www.clinicaltrialresults.org. Accessed May, 1 2014.
14. Patti G, Pasceri V, D'Antonio L, et al. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study). Am J Cardiol 2012;110:478-84.
15. Schulz S, Richardt G, Laugwitz KL, et al. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Eur Heart J 2014;35:2285-94.
16. Yaling H. Bivalirudin versus Heparin Monotherapy and Glycoprotein IIb/IIIa Plus Heparin for Patients with AMI Undergoing Coronary Stenting - Six-month results of the BRIGHT study. Presented at China Interventional Therapeutics in partnership with TCT (CIT 2014), March 20-23, 2014, Beijing, China.
17. Steg PG, van't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207-17.
18. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008;358:2218-30.
19. Kastrati A, Neumann F-J, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008;359:688-96.
20. Kastrati A, Neumann F-J, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011;365:1980-9.
21. Gibson CM, Morrow DA, Murphy SA, et al. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006;47:2364-73.
22. Ray MJ, Juneja M, Bett N, Walters DL. A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. EuroIntervention 2009;5:330-5.
23. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.
24. Rajagopal V, Lincoff AM, Cohen DJ, et al. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Am Heart J 2006;152:149-54.
25. Antman EM, McCabe CH, Braunwald E. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: Observations from the TIMI 8 trial. Am Heart J 2002;143:229-34.
26. Dangas GD, Claessen BE, Mehran R, et al. Clinical outcomes following stent thrombosis occurring in-hospital versus out-of-hospital: results from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol 2012;59:1752-9.
27. Dangas GD, Caixeta A, Mehran R, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011;123:1745-56.
28. Stone G, Witzenbichler B, Guagliumi G. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011;377:2193-204.
29. Tarantini G, Brener SJ, Barioli A, et al. Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a metaregression analysis of randomized trials. Am Heart J 2014;167:401-412.e6.
30. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142-54.
31. Navarese EP, Kozinski M, Obonska K, et al. Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. Platelets 2012;23:274-81.